Recommended

AVAILABLE TO WATCH NOW | Discover how to understand pain pathways and accelerate the search for next-generation analgesics
The truth about AI in drug discovery: what the experts really think | REGISTER FOR THE FREE WEBINAR
ACCESS THE FREE RECORDING | Top cancer researchers explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
NEW REPORT | Explore how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
The scientific advances driving cancer drug discovery – find out more
Meet the precision peptide changing how we study pain
news

BenevolentAI becomes first AI company to appoint a Chief Medical Officer

BenevolentAI is the first AI company to have a CMO on its staff.

The British artificial intelligence company BenevolentAI has appointed Dr Patrick Keohane as Chief Medical Officer.  

Dr Patrick Keohane

AI in bioscience

Patrick will take up the position of CMO of BenevolentBio – a subsidiary of BenevolentAI that applies its unique and disruptive AI technology to accelerate a pipeline of better medicines for patients and to explore further applications for AI in bioscience.  He will work with BenevolentBio’s expanding team of experienced drug discovery scientists, technology experts, and bioscience researchers to rapidly identify and progress novel therapies into early and late stage clinical trials.

Dr Keohane

With over 20 years of experience, Dr Keohane trained as a Gastroenterologist in the NHS and worked for the Medical Research Council. He has held senior management positions in Research and Development at Eli Lilly and AstraZeneca, and has worked in the US, Japan and Europe. He joins the Company from Glenmark Pharmaceuticals, where he held the position of Chief Medical Officer.

 

access your free copy

 


Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing

This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Inside the report:

  • Advance discovery through miniaturised, high-throughput and animal-free systems
  • Integrate AI, robotics and analytics to speed decision-making
  • Streamline cell therapy and bioprocess QC for scale and compliance
  • And more!

This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today

 

BenevolentAI

BenevolentAI is a British technology company harnessing the power of AI to enhance and accelerate scientific discovery and innovation.  The Company was founded to explore the application of AI in the field of bioscience and has since diversified its technology for applications across many scientific industries. BenevolentAI’s focus is applying AI where the partnership between scientist and technology can create new discoveries that benefit society and address some of the world’s most pressing challenges.

BenevolentBio, a subsidiary of BenevolentAI, focuses on turning the world’s mass of highly fragmented biomedical knowledge and pharmaceutical R&D data into useable new information and insight.  This validated technology has significantly accelerated the process of drug discovery and development in order to bring new medicines to patients more efficiently.

Professor Jackie Hunter, CEO of BenevolentBio commented, “Patrick’s appointment fits perfectly with our ethos of integrating scientific expertise and technology to revolutionise the drug development process. He brings extensive experience in the worldwide development of medicines and will play a key part in the development of our strong clinical pipeline.